CONTROL BIONICS LIMITED — Investor Presentation 2023

Jul 23, 2023

==> picture [231 x 76] intentionally omitted <==

Bioshares Biotech Summit

PRESENTED BY: Jeremy Steele DATE PRESENTED: 24 July 2023 Private & Confidential. Copyright © Control Bionics 2023

DISCLAIMER

==> picture [315 x 5] intentionally omitted <==

==> picture [720 x 405] intentionally omitted <==

----- Start of picture text -----

Our flagship product
----- End of picture text -----

Who is Control Bionics?

==> picture [229 x 114] intentionally omitted <==

4

Our technology

==> picture [213 x 205] intentionally omitted <==

----- Start of picture text -----

How it works
----- End of picture text -----

5

Current Uses of our technology

==> picture [213 x 205] intentionally omitted <==

6

Our sales and market strategy

	Team	Sales Channels	Pricing and reimbursement
USA	23 Staff 10 Sales	US sells directly to end users through relationships with speech language pathologists (‘SLPs’). We also have distributors who sell our solutions. In addition, we have partnership relationships with other volume customers such as the Veterans Administration (‘VA’) and certain US school districts	Dependent on the payor. Mix of payors in the US include Medicare, Medicaid, Private Health Insurance, private pay, the VA and schools. Reimbursement ranges from US$5k – US$18k dependent on payor and products
Australia	14 Staff 5 Sales	Australia sells directly to end users through relationships with SLPs who advise their clients on technology solutions. We also have an ever- growing pool of customers who are a hub for potential clients such as private and public rehab groups, disease bodies (such as MND and CP) and specialised schools and education institutions	Majority of customers are funded through the NDIS. Reimbursement ranges from A$3k – A$22k dependent on product mix determined best for the client
Japan	3 Staff	Recent refinement of strategy in Japan has seen CBL move to more direct sales of our Neuronode. The Neuronode is seen as a high-quality standalone add-on to existing local technology. While continuing with our local distributor, our staff will work directly with rehab and other specialised hospitals to sell directly into end users	Japan is a largely ‘unfunded’ market so predominately self-pay. Pricing US$5- US$10k
Rest of World		As the current investment in our software is released, we will open up opportunities to wholesale the Neuronode to other market players as an add on to their existing product suite (an extension of our Japanese strategy). Given we already have a CE Mark combined with the developed nature of the market, Europe is our most likely next region to target	Pricing dependent on volume. Not currently disclosing this commercially sensitive information

Competitor Landscape

==> picture [229 x 114] intentionally omitted <==

8

Our Future Technology

R&D

DROVE

wheelchair that they have never enjoyed https://www.youtube.com/watch?v=XaSuMlTb4H0

Neuronode as a diagnostics device

==> picture [78 x 323] intentionally omitted <==

HOW GOOD IS THE OPPORTUNITY FOR CONTROL BIONICS?

There is a significant underserved market in this space with growth available to Control Bionics in its existing core

We have identified a number of opportunities to extend the use of our core IP , the Neuronode, into new

• We expect FY24 to be a significant year for Control Bionics and would welcome partners and investors to support our near term growth opportunities

10

THANK YOU

JEREMY STEELE

jsteele@controlbionics.com +65 9011 3975

www.controlbionics.com